Drug
Elbasvir clinical trials
Also written MK-8742.
- studies test it
- 19
- open now
- 0
- in phase 3
- 8
- first study started
- 2012
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
19 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 8
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 8
Merck Sharp & Dohme LLC (11) · Fundacion Clinic per a la Recerca Biomédica (2) · University Hospital, Clermont-Ferrand (1) · Kyushu University (1) · Taoyuan General Hospital (1) · University of Zurich (1) · Norte Study Group (1) · Istituto Clinico Humanitas (1)
Often tested with
Tested in the same studies.
Grazoprevir (15) · Ribavirin (4) · Uprifosbuvir (2) · Ruzasvir (2) · Sofosbuvir (1) · MK-3682B (1)
Studies
Open first, then newest update. How each study uses elbasvir is read from its arms, and is right about nine times in ten.
Testing it · 19
- Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe FibrosisCompletedPhase 3University Hospital, Clermont-FerrandNCT02973503Written as Elbasvir/Grazoprevir Fixed Dose Combination
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.WithdrawnPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT02890719Written as Elbasvir 50 mg/d
- Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)CompletedPhase 2Merck Sharp & Dohme LLCNCT02133131Written as Grazoprevir/Elbasvir FDC
- Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)CompletedPhase 2Merck Sharp & Dohme LLCNCT01932762Written as Elbasvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332720Written as Elbasvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Elbasvir
- The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)CompletedPhase 1Merck Sharp & Dohme LLCNCT01937975Written as Elbasvir
- A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus ElbasvirCompletedPhase 4Kyushu UniversityNCT03144635Written as Grazoprevir plus Elbasvir
- Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected PatientsStatus unknownPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT02897596Written as Elbasvir 50 mg/d 8 weeks
- Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infectionCompletedPhase 4Taoyuan General HospitalNCT03098121Written as grazoprevir and elbasvir
- The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT01797536Written as Elbasvir
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)CompletedPhase 3Merck Sharp & Dohme LLCNCT02252016Written as Grazoprevir + Elbasvir
- Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02092350Written as Elbasvir
- Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)CompletedPhase 2Merck Sharp & Dohme LLCNCT02105454Written as Elbasvir (EBR)
- Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02203149Written as Elbasvir
- Swiss HCVree TrialCompletedPhase 3University of ZurichNCT02785666Written as grazoprevir/elbasvir, ribavirin
- Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT01532973Written as Elbasvir
- Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis CStatus unknownPhase 4Norte Study GroupNCT03022006Written as elbasvir, grazoprevir
- Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated CirrhosisStatus unknownPhase 3Istituto Clinico HumanitasNCT02732405Written as MK5172 /MK8742
Given in every arm · 5 — elbasvir is usual care beside what is tested
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)CompletedPhase 2Merck Sharp & Dohme LLCNCT03379506Written as Elbasvir Oral Granules
- A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)CompletedPhase 2Merck Sharp & Dohme LLCNCT01717326Written as Elbasvir
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)CompletedPhase 3Merck Sharp & Dohme LLCNCT02105701Written as Grazoprevir + Elbasvir
- Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedPhase 2Merck Sharp & Dohme LLCNCT02601573Written as Elbasvir
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02115321Written as Elbasvir
As the comparator · 1 — what is tested is compared with elbasvir
Codes
What other systems call elbasvir · ClinicalTrials.gg INT000027
- MeSH (NLM) C000589335elbasvirOne source NLM
- UNII (FDA) 632L571YDKELBASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1734628Confirmed FDA, Wikidata
- Wikidata Q19904043elbasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166892ElbasvirOne source FDA
- DrugBank DB11574One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589335 | elbasvir | One source NLM |
| UNII (FDA) | 632L571YDK | ELBASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1734628 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19904043 | elbasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166892 | Elbasvir | One source FDA |
| DrugBank | DB11574 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.